Skip to content
Catalyst

NAD(+)What was measured

Measured, with no finding

382 endpoints

Show what was measuredHide what was measured
  • favorable response

    increases, n = 26

    Within this cohort of 26 patients, 8 of 26 (31%) responded favorably to NADH in contrast to 2 of 26 (8%) to placebo

    PMID 10071523 · one of two readings recorded this

  • proportion of CFS patients who responded favorably, response criterion not stated in the abstract (questionnaire, laboratory and physical examination data at 4, 8 and 12 weeks)

    increases, 8 of 26 (31%) responded to NADH vs 2 of 26 (8%) to placebo, n = 26

    Not recorded as a finding: the paper never states the instrument the node requires

    Within this cohort of 26 patients, 8 of 26 (31%) responded favorably to NADH in contrast to 2 of 26 (8%) to placebo.

    PMID 10071523 · one of two readings recorded this

  • proportion of chronic fatigue syndrome patients responding favorably, global responder rate

    increases, 8 of 26 (31%) on NADH vs 2 of 26 (8%) on placebo, n = 26

    Not recorded as a finding: this platform holds no node for the endpoint

    Within this cohort of 26 patients, 8 of 26 (31%) responded favorably to NADH in contrast to 2 of 26 (8%) to placebo.

    PMID 10071523 · one of two readings recorded this

  • cognitive test measures (Cog Screen and other computer-administered tests)

    increases, p = 0.05

    Individuals who received NADH performed significantly better on 4 cognitive test measures (P < or = .05) and reported less sleepiness compared with those who received placebo

    PMID 12385067 · one of two readings recorded this

  • jet lag-induced cognitive performance on four unnamed computer-administered test measures (Cog Screen) and self-reported sleepiness, morning and afternoon after an overnight flight

    increases, NADH performed significantly better on 4 cognitive test measures (P < or = .05) and reported less sleepiness than placebo

    Not recorded as a finding: this platform holds no node for the endpoint

    Individuals who received NADH performed significantly better on 4 cognitive test measures (P < or = .05) and reported less sleepiness compared with those who received placebo.

    PMID 12385067 · one of two readings recorded this

  • performance on 4 computer-administered cognitive test measures (Cog Screen) and self-reported sleepiness after jet lag

    increases, significantly better on 4 cognitive test measures and less sleepiness vs placebo

    Not recorded as a finding: this platform holds no node for the endpoint

    Individuals who received NADH performed significantly better on 4 cognitive test measures (P < or = .05) and reported less sleepiness compared with those who received placebo.

    PMID 12385067 · one of two readings recorded this

  • sleepiness

    decreases

    Individuals who received NADH performed significantly better on 4 cognitive test measures (P < or = .05) and reported less sleepiness compared with those who received placebo

    PMID 12385067 · one of two readings recorded this

  • elevated IgG and IgE antibody levels

    Elevated IgG and Ig E antibody levels were found in a significant number of patients

    PMID 15377055 · one of two readings recorded this

  • mean symptom score from a fatigue and other-symptoms questionnaire, per trimester

    decreases, dramatic and statistically significant reduction of the mean symptom score in the first trimester in the NADH group, p < 0.001; similar in both groups thereafter, n = 12

    Not recorded as a finding: the comparison was against another active treatment

    The twelve patients who received NADH had a dramatic and statistically significant reduction of the mean symptom score in the first trimester (p < 0.001).

    PMID 15377055 · one of two readings recorded this

  • mean symptom score

    decreases, p = 0.001

    The twelve patients who received NADH had a dramatic and statistically significant reduction of the mean symptom score in the first trimester (p < 0.001)

    PMID 15377055 · one of two readings recorded this

  • mean symptom score

    no effect

    However, symptom scores in the subsequent trimesters of therapy were similar in both treatment groups

    PMID 15377055 · one of two readings recorded this

  • glucose-stimulated insulin secretion regulated by Sirt1 via Ucp2 repression

    decreases

    Here, we report that as this same cohort of BESTO mice reaches 18-24 months of age, the GSIS regulated by Sirt1 through repression of Ucp2 is blunted.

    PMID 18005249 · one of two readings recorded this

  • GSIS and glucose tolerance

    increases

    Furthermore, NMN administration restores enhanced GSIS and improved glucose tolerance in the aged BESTO females, suggesting that Sirt1 activity decreases with advanced age due to a decline in systemic NAD biosynthesis.

    PMID 18005249 · one of two readings recorded this

  • plasma nicotinamide mononucleotide (NMN)

    decreases

    Interestingly, plasma levels of nicotinamide mononucleotide (NMN), an important metabolite for the maintenance of normal NAD biosynthesis and GSIS in beta cells, are significantly reduced in aged BESTO mice.

    PMID 18005249 · one of two readings recorded this

  • time and distance run before exhaustion

    no effect, n = 24

    The time and distance run before exhaustion was similar in the three groups (data not shown), around 600 meters after 40 minutes of exercise

    PMID 19262508 · one of two readings recorded this

  • brain NAD(+) levels and ischemic infarct size

    increases

    Administration of nicotinamide (200 mg/kg, i.p.) up to 1 h after the onset of ischemia elevated brain NAD(+) levels and reduced ischemic infarct size.

    PMID 19288225 · one of two readings recorded this

  • cellular NAD(P)H levels and mitochondrial membrane potential

    decreases

    Excitotoxic activation of NMDA receptors induced a rapid decrease of cellular NAD(P)H levels and mitochondrial membrane potential.

    PMID 19288225 · one of two readings recorded this

  • glutamate/NMDA-induced NAD(+) depletion and death

    no effect

    Treatment of neurons with the SIRT1 activator resveratrol did not protect them from glutamate/NMDA-induced NAD(+) depletion and death.

    PMID 19288225 · one of two readings recorded this

  • NAD(+) levels and PAR accumulation timing

    decreases

    Decreased NAD(+) levels and poly (ADP-ribose) polymer (PAR) accumulation in nuclei were relatively early events (<4 h) that preceded the appearance of propidium iodide- and TUNEL-positive cells

    PMID 19288225 · one of two readings recorded this

  • NAD(+) levels, PAR accumulation and neuronal death

    increases

    NAD(+) levels were preserved and PAR accumulation and neuronal death induced by excitotoxic insults were attenuated in nicotinamide-treated cells.

    PMID 19288225 · one of two readings recorded this

  • NAD(+) levels

    decreases

    In a mouse model of focal cerebral ischemic stroke, NAD(+) levels were decreased in both the contralateral and ipsilateral cortex 6 h after the onset of ischemia.

    PMID 19288225 · one of two readings recorded this

  • SIRT1 deacetylase activity

    decreases

    Nicotinamide, an NAD(+) precursor and an inhibitor of SIRT1 and PARP1, inhibited SIRT1 deacetylase activity without affecting SIRT1 protein levels.

    PMID 19288225 · one of two readings recorded this

  • serum adiponectin

    no effect

    Adiponectin levels were similar for wild-type, AMPKα1−/−, and AMPKα2−/− mice and were not changed by resveratrol

    PMID 19934007 · one of two readings recorded this

  • body weight curve, high-fat diet vs resveratrol

    decreases, p = 0.003

    The body weight curves between high-fat diet and resveratrol were statistically significant for wild-type (P = 0.003) and AMPKα2−/− (P = 0.02) mice

    PMID 19934007 · one of two readings recorded this

  • body weight curve, high-fat diet vs resveratrol

    decreases, p = 0.02

    The body weight curves between high-fat diet and resveratrol were statistically significant for wild-type (P = 0.003) and AMPKα2−/− (P = 0.02) mice

    PMID 19934007 · one of two readings recorded this

  • body weight

    no effect

    Resveratrol reduced the body weight of wild-type and AMPKα2−/− mice but not that of AMPKα1−/− mice

    PMID 19934007 · one of two readings recorded this

  • fasting insulin

    decreases

    However, resveratrol dramatically decreased the fasting insulin levels in wild-type, AMPKα1−/−, and AMPKα2−/− mice even though resveratrol increased insulin sensitivity only in wild-type mice

    PMID 19934007 · one of two readings recorded this

  • fat mass index

    unclear, p = 0.07

    # P = 0.07 between high-fat diet and resveratrol for AMPKα2−/− mice

    PMID 19934007 · one of two readings recorded this

  • glucose tolerance curve

    increases, p = 0.001

    Glucose tolerance curves between high-fat diet and resveratrol were significant for wild-type mice (P = 0.001) but not for AMPKα1−/− (P = 0.8) and AMPKα2−/− (P = 0.053) mice

    PMID 19934007 · one of two readings recorded this

  • glucose tolerance curve

    no effect, p = 0.8

    Glucose tolerance curves between high-fat diet and resveratrol were significant for wild-type mice (P = 0.001) but not for AMPKα1−/− (P = 0.8) and AMPKα2−/− (P = 0.053) mice

    PMID 19934007 · one of two readings recorded this

  • glucose tolerance curve

    no effect, p = 0.053

    Glucose tolerance curves between high-fat diet and resveratrol were significant for wild-type mice (P = 0.001) but not for AMPKα1−/− (P = 0.8) and AMPKα2−/− (P = 0.053) mice

    PMID 19934007 · one of two readings recorded this

  • insulin sensitivity curve

    increases, p = 0.01

    Insulin sensitivity curves between high-fat diet (●) and resveratrol (○) were significant for wild-type (WT) mice (P = 0.01)

    PMID 19934007 · one of two readings recorded this

  • intramyocellular DAG and ceramide

    decreases

    As shown in Fig. 4 D and E, resveratrol decreased DAG and ceramide levels in wild-type mice but not in AMPKα1−/− and AMPKα2−/− mice

    PMID 19934007 · one of two readings recorded this

  • metabolic rate (Vo2)

    increases

    Resveratrol increased the metabolic rate of wild-type mice, but it did not increase the metabolic rate of AMPKα1−/− mice

    PMID 19934007 · one of two readings recorded this

  • mitochondrial content (cytochrome C and mtDNA)

    increases

    Consistent with this, resveratrol increased the mitochondrial content, as measured by cytochrome C and mitochondrial DNA levels, in wild-type muscle but not in AMPKα1−/− or AMPKα2−/− muscle

    PMID 19934007 · one of two readings recorded this

  • NAD and NAD-to-NADH ratio in skeletal muscle

    no effect

    NAD and the NAD-to-NADH ratio in skeletal muscle were increased by resveratrol in wild-type mice but not in AMPKα1−/− or AMPKα2−/− mice

    PMID 19934007 · one of two readings recorded this

  • NAD and NAD-to-NADH ratio in skeletal muscle

    increases

    NAD and the NAD-to-NADH ratio in skeletal muscle were increased by resveratrol in wild-type mice but not in AMPKα1−/− or AMPKα2−/− mice

    PMID 19934007 · one of two readings recorded this

  • NAD-to-NADH ratio

    increases

    As shown in Fig. 5 A, resveratrol increased the NAD-to-NADH ratio by >30%

    PMID 19934007 · one of two readings recorded this

  • PGC-1α acetylation

    decreases

    As shown in Fig. 5 C, resveratrol decreased the acetylation level of PGC-1α only in wild-type mice

    PMID 19934007 · one of two readings recorded this

  • physical endurance (treadmill distance)

    increases

    As reported previously, resveratrol increased physical endurance (309.2 ± 37 vs. 212.3 ± 19 m) of wild-type mice

    PMID 19934007 · one of two readings recorded this

  • physical endurance

    no effect

    However, resveratrol did not increase the physical endurance of AMPKα1−/− or AMPKα2−/− mice

    PMID 19934007 · one of two readings recorded this

  • ROS level in skeletal muscle

    decreases

    Resveratrol reduced ROS levels in wild-type mice by almost 30% but not in AMPKα1−/− or AMPKα2−/− mice

    PMID 19934007 · one of two readings recorded this

  • anxiety condition (instrument not stated) and maximum heart rate after a stress test

    decreases, anxiety -1.0 points (p<0.05) in the NADH group vs -0.2 points (p=NS) in the placebo group, each a within-group change

    Not recorded as a finding: the result compares a group with itself, not with a control

    Administration of NADH was associated to a decrease in anxiety condition of -1.0 points (p<0.05) and of -0.2 points (p=NS) in the placebo assigned group.

    PMID 20447621 · one of two readings recorded this

  • anxiety condition score change, instrument not named in the abstract

    decreases, -1.0 points on NADH vs -0.2 points (p=NS) on placebo

    Not recorded as a finding: the paper never states the instrument the node requires

    Administration of NADH was associated to a decrease in anxiety condition of -1.0 points (p<0.05) and of -0.2 points (p=NS) in the placebo assigned group.

    PMID 20447621 · one of two readings recorded this

  • anxiety condition

    decreases, p = 0.05

    Administration of NADH was associated to a decrease in anxiety condition of -1.0 points (p<0.05) and of -0.2 points (p=NS) in the placebo assigned group

    PMID 20447621 · one of two readings recorded this

  • anxiety condition

    no effect

    Administration of NADH was associated to a decrease in anxiety condition of -1.0 points (p<0.05) and of -0.2 points (p=NS) in the placebo assigned group

    PMID 20447621 · one of two readings recorded this

  • maximum heart rate after stress test

    decreases, p = 0.05

    Maximum heart rate after the stress test decreased a mean of -8.1l/min (p<0.05) in the NADH group and increased by +1.7l/min in the placebo group (p=0.73)

    PMID 20447621 · one of two readings recorded this

  • maximum heart rate after stress test

    no effect, p = 0.73

    Maximum heart rate after the stress test decreased a mean of -8.1l/min (p<0.05) in the NADH group and increased by +1.7l/min in the placebo group (p=0.73)

    PMID 20447621 · one of two readings recorded this

  • glucose intolerance and lipid profiles in age-induced T2D mice

    decreases

    Furthermore, NAD(+) and NAMPT levels show significant decreases in multiple organs during aging, and NMN improves glucose intolerance and lipid profiles in age-induced T2D mice.

    PMID 21982712 · one of two readings recorded this

  • glucose intolerance and NAD(+) levels in HFD-induced T2D mice

    decreases

    Strikingly, nicotinamide mononucleotide (NMN), a product of the NAMPT reaction and a key NAD(+) intermediate, ameliorates glucose intolerance by restoring NAD(+) levels in HFD-induced T2D mice.

    PMID 21982712 · one of two readings recorded this

  • hepatic insulin sensitivity

    increases

    NMN also enhances hepatic insulin sensitivity and restores gene expression related to oxidative stress, inflammatory response, and circadian rhythm, partly through SIRT1 activation.

    PMID 21982712 · one of two readings recorded this

  • NAD(+) and NAMPT levels across organs

    decreases

    Furthermore, NAD(+) and NAMPT levels show significant decreases in multiple organs during aging, and NMN improves glucose intolerance and lipid profiles in age-induced T2D mice.

    PMID 21982712 · one of two readings recorded this

  • NAD(+) biosynthesis (NAMPT-mediated) in metabolic organs

    decreases

    Here, we show that NAMPT-mediated NAD(+) biosynthesis is severely compromised in metabolic organs by high-fat diet (HFD).

    PMID 21982712 · one of two readings recorded this

  • intracellular cAMP

    increases

    Here, we report that the metabolic effects of resveratrol result from competitive inhibition of cAMP-degrading phosphodiesterases, leading to elevated cAMP levels.

    PMID 22304913 · one of two readings recorded this

  • intracellular NAD(+)

    increases

    As a consequence, resveratrol increases NAD(+) and the activity of Sirt1.

    PMID 22304913 · one of two readings recorded this

  • metabolic benefits (diet-induced obesity, mitochondrial function, physical stamina, glucose tolerance) in mice

    increases

    Inhibiting PDE4 with rolipram reproduces all of the metabolic benefits of resveratrol, including prevention of diet-induced obesity and an increase in mitochondrial function, physical stamina, and glucose tolerance in mice.

    PMID 22304913 · one of two readings recorded this

  • Sirt1 activity

    increases

    As a consequence, resveratrol increases NAD(+) and the activity of Sirt1.

    PMID 22304913 · one of two readings recorded this

  • AMPK activation

    increases

    A high dose of resveratrol activated AMPK in a SIRT1-independent manner, demonstrating that resveratrol dosage is a critical factor

    PMID 22560220 · one of two readings recorded this

  • skeletal muscle NAD(+) levels

    increases

    Mice treated with a moderate dose of resveratrol showed increased mitochondrial biogenesis and function, AMPK activation, and increased NAD(+) levels in skeletal muscle, whereas SIRT1 knockouts displayed none of these benefits

    PMID 22560220 · one of two readings recorded this

  • skeletal muscle NAD(+) levels

    no effect

    Mice treated with a moderate dose of resveratrol showed increased mitochondrial biogenesis and function, AMPK activation, and increased NAD(+) levels in skeletal muscle, whereas SIRT1 knockouts displayed none of these benefits

    PMID 22560220 · one of two readings recorded this

  • mitochondrial-encoded OXPHOS subunits

    decreases

    We show that, during aging, there is a specific loss of mitochondrial, but not nuclear, encoded OXPHOS subunits

    PMID 24360282 · one of two readings recorded this

  • mitochondrial function

    increases

    Deleting SIRT1 accelerates this process, whereas raising NAD(+) levels in old mice restores mitochondrial function to that of a young mouse in a SIRT1-dependent manner

    PMID 24360282 · one of two readings recorded this

  • BAL injury indices

    decreases

    FK-866-mediated iNAMPT inhibition successfully reduced lung tissue iNAD levels, BAL injury indices, inflammatory cell infiltration, and lung injury scores in LPS- and VILI-exposed mice

    PMID 24588101 · one of two readings recorded this

  • inflammatory cell infiltration

    decreases

    FK-866-mediated iNAMPT inhibition successfully reduced lung tissue iNAD levels, BAL injury indices, inflammatory cell infiltration, and lung injury scores in LPS- and VILI-exposed mice

    PMID 24588101 · one of two readings recorded this

  • lung injury scores

    decreases

    FK-866-mediated iNAMPT inhibition successfully reduced lung tissue iNAD levels, BAL injury indices, inflammatory cell infiltration, and lung injury scores in LPS- and VILI-exposed mice

    PMID 24588101 · one of two readings recorded this

  • lung tissue iNAD level

    decreases

    FK-866-mediated iNAMPT inhibition successfully reduced lung tissue iNAD levels, BAL injury indices, inflammatory cell infiltration, and lung injury scores in LPS- and VILI-exposed mice

    PMID 24588101 · one of two readings recorded this

  • PMN apoptosis (caspase-3 activation in BAL PMNs)

    increases

    FK-866 further increased lung PMN apoptosis, as reflected by caspase-3 activation in BAL PMNs

    PMID 24588101 · one of two readings recorded this

  • early- and late-stage disease progression

    decreases

    This vitamin effectively delayed early- and late-stage disease progression, by robustly inducing mitochondrial biogenesis in skeletal muscle and brown adipose tissue, preventing mitochondrial ultrastructure abnormalities and mtDNA deletion formation

    PMID 24711540 · one of two readings recorded this

  • mitochondrial biogenesis

    increases

    This vitamin effectively delayed early- and late-stage disease progression, by robustly inducing mitochondrial biogenesis in skeletal muscle and brown adipose tissue, preventing mitochondrial ultrastructure abnormalities and mtDNA deletion formation

    PMID 24711540 · one of two readings recorded this

  • mitochondrial ultrastructure abnormalities and mtDNA deletion formation

    decreases

    This vitamin effectively delayed early- and late-stage disease progression, by robustly inducing mitochondrial biogenesis in skeletal muscle and brown adipose tissue, preventing mitochondrial ultrastructure abnormalities and mtDNA deletion formation

    PMID 24711540 · one of two readings recorded this

  • mitochondrial unfolded protein response

    increases

    NR further stimulated mitochondrial unfolded protein response, suggesting its protective role in mitochondrial disease

    PMID 24711540 · one of two readings recorded this

  • LDL cholesterol and 1-carbon metabolism

    no effect

    NR also did not elevate low density lipoprotein cholesterol or dysregulate 1-carbon metabolism

    PMID 31278280 · one of two readings recorded this

  • whole blood NAD+

    increases

    Consumption of 100, 300 and 1000 mg NR dose-dependently and significantly increased whole blood NAD+ (i.e., 22%, 51% and 142%) and other NAD+ metabolites within 2 weeks

    PMID 31278280 · one of two readings recorded this

  • whole blood NAD+

    increases

    Consumption of 100, 300 and 1000 mg NR dose-dependently and significantly increased whole blood NAD+ (i.e., 22%, 51% and 142%) and other NAD+ metabolites within 2 weeks

    PMID 31278280 · one of two readings recorded this

  • whole blood NAD+

    increases

    Consumption of 100, 300 and 1000 mg NR dose-dependently and significantly increased whole blood NAD+ (i.e., 22%, 51% and 142%) and other NAD+ metabolites within 2 weeks

    PMID 31278280 · one of two readings recorded this

  • circulating inflammatory cytokines

    decreases, n = 12

    NR also depressed levels of circulating inflammatory cytokines

    PMID 31412242 · one of two readings recorded this

  • skeletal muscle energy metabolism and mitochondria pathway gene expression

    decreases, n = 12

    Muscle RNA sequencing revealed NR-mediated downregulation of energy metabolism and mitochondria pathways, without altering mitochondrial bioenergetics

    PMID 31412242 · one of two readings recorded this

  • skeletal muscle mitochondrial bioenergetics

    no effect, n = 12

    Muscle RNA sequencing revealed NR-mediated downregulation of energy metabolism and mitochondria pathways, without altering mitochondrial bioenergetics

    PMID 31412242 · one of two readings recorded this

  • skeletal muscle NAD+ metabolome (NAAD and nicotinamide clearance products)

    increases, n = 12

    Targeted metabolomics showed that NR elevated the muscle NAD+ metabolome, evident by increased nicotinic acid adenine dinucleotide and nicotinamide clearance products

    PMID 31412242 · one of two readings recorded this

  • lymphocyte tail DNA percentage (TD)

    no effect, p = 0.05

    However, no significant difference was observed between the groups (p > 0.05)

    PMID 32545655 · one of two readings recorded this

  • lymphocyte tail DNA percentage (TD)

    increases, p = 0.05

    TD was significantly increased in all groups at IAE rather than at IBE and significantly decreased at 30 MAE (p < 0.05)

    PMID 32545655 · one of two readings recorded this

  • lymphocyte tail length (TL)

    increases, p = 0.05

    both CC + MF and CC + HF groups exhibited significantly higher values than the T + HF group at 30 MAE (p < 0.05)

    PMID 32545655 · one of two readings recorded this

  • lymphocyte tail length (TL)

    increases, p = 0.05

    the TL was significantly higher in the CC + MF group than in the T + HF group at IAE (p < 0.05)

    PMID 32545655 · one of two readings recorded this

  • lymphocyte tail length (TL)

    increases, p = 0.05

    All groups showed a significant increase in TL at IAE rather than at IBE and significantly reduced at 30 MAE (p < 0.05)

    PMID 32545655 · one of two readings recorded this

  • lymphocyte tail moment (TM)

    increases, p = 0.05

    TM of the CC + MF group was significantly higher than that of the CC + HF and T + HF groups at IAE and 30 MAE (p < 0.05)

    PMID 32545655 · one of two readings recorded this

  • lymphocyte tail moment (TM)

    increases, p = 0.05

    TM was significantly higher in the T + MF group than in the T + HF group at IAE (p < 0.05)

    PMID 32545655 · one of two readings recorded this

  • lymphocyte tail moment (TM)

    increases, p = 0.05

    TM was significantly higher in all groups at the IAE rather than at the IBE and significantly decreased at 30 MAE (p < 0.05)

    PMID 32545655 · one of two readings recorded this

  • plasma lactate

    no effect, p = 0.05

    no significant difference was observed between the groups (p > 0.05)

    PMID 32545655 · one of two readings recorded this

  • plasma lactate

    increases, p = 0.05

    All groups displayed a significant increase in plasma lactate levels at IAE rather than at IBE and significant reduction at 30 MAE (p < 0.05)

    PMID 32545655 · one of two readings recorded this

  • plasma MDA

    increases, p = 0.05

    plasma MDA levels were significantly higher in the CC + MF group than in the T + HF group at IAE (p < 0.05)

    PMID 32545655 · one of two readings recorded this

  • plasma MDA

    increases, p = 0.05

    All groups displayed a significant increase in plasma MDA levels at IAE rather than at IBE, and the CC + HF and T + HF groups presented a significant reduction at 30 MAE (p < 0.05)

    PMID 32545655 · one of two readings recorded this

  • plasma SOD activity

    no effect, p = 0.05

    However, no significant difference was observed between the groups (p > 0.05)

    PMID 32545655 · one of two readings recorded this

  • plasma SOD activity

    increases, p = 0.05

    Plasma SOD activity was significantly increased in all groups at IAE rather than at IBE and significantly decreased at 30 MAE (p < 0.05)

    PMID 32545655 · one of two readings recorded this

  • ALP 0 h and 48 h by Step

    ALP (U/l) | 109.8 ± 47.2 | 105.0 ± 33.9 | 116.3 ± 64.4 | 143.5 ± 62.9 | 148.0 ± 120.2 | 117.3 ± 65.1 | 86.3 ± 39.7 | 91.3 ± 38.5 | 79.8 ± 29.3 | 111.6 ± 37.3

    PMID 32791973 · one of two readings recorded this

  • ALT 0 h and 48 h by Step

    ALT (U/l) | 14.5 ± 3.9 | 13.0 ± 1.4 | 24.5 ± 7.1 | 103.0 ± 117.4 | 15.8 ± 3.1 | 18.8 ± 5.7 | 20.2 ± 12.1 | 23.0 ± 15.7 | 15.6 ± 7.5 | 18.0 ± 6.7

    PMID 32791973 · one of two readings recorded this

  • AST 0 h and 48 h by Step

    AST (U/l) | 20.0 ± 6.6 | 19.5 ± 2.1 | 25.0 ± 9.8 | 60.5 ± 55.9 | 33.8 ± 12.7 | 33.0 ± 2.8 | 27.2 ± 8.6 | 27.7 ± 17.8 | 25.6 ± 13.3 | 24.0 ± 1.9

    PMID 32791973 · one of two readings recorded this

  • blood urea nitrogen (NRPT vs placebo)

    decreases

    Blood urea nitrogen (BUN) was lower at 48 h in patients treated with NRPT compared to placebo

    PMID 32791973 · one of two readings recorded this

  • BUN 0 h and 48 h by Step

    BUN (mg/dl) | 45.0 ± 28.1 | 63.5 ± 29.0 | 36.8 ± 15.6 | 34.6 ± 12.1 | 33.5 ± 9.3 | 28.0 ± 13.1 | 35.6 ± 12.6 | 37.3 ± 9.3 | 28.4 ± 12.0 | 28.6 ± 16.2

    PMID 32791973 · one of two readings recorded this

  • creatinine and eGFR (NRPT vs placebo)

    no effect

    Compared to placebo, there was no significant difference in creatinine and eGFR in patients treated with NRPT at 48 h

    PMID 32791973 · one of two readings recorded this

  • eGFR 0 h and 48 h by Step

    eGFR (ml/min/1.73m2) | 41.3 ± 21.1 | 25.0 ± 7.1 | 43.2 ± 9.9 | 47.8 ± 11.5 | 42.0 ± 20.4 | 50.0 ± 28.1 | 39.2 ± 13.3 | 41.3 ± 15.7 | 46.4 ± 21.8 | 43.6 ± 17.5

    PMID 32791973 · one of two readings recorded this

  • hemoglobin 0 h and 48 h by Step

    Hgb (g/dl) | 11.0 ± 2.0 | 9.9 ± 3.1 | 10.9 ± 2.9 | 11.4 ± 3.0 | 11.1 ± 3.3 | 10.8 ± 3.3 | 10.3 ± 1.7 | 10.7 ± 1.5 | 11.3 ± 2.0 | 11.1 ± 2.4

    PMID 32791973 · one of two readings recorded this

  • platelet count 0 h and 48 h by Step

    PLT (K/μl) | 207.3 ± 37.3 | 225.5 ± 17.7 | 202.8 ± 68.7 | 240.0 ± 28.1 | 260.5 ± 74.5 | 234.3 ± 59.4 | 286.0 ± 136.7 | 238.0 ± 74.7 | 268.3 ± 75.6 | 269.0 ± 108.4

    PMID 32791973 · one of two readings recorded this

  • serum creatinine 0 h and 48 h by Step

    Cr (mg/dl) | 1.52 ± 0.45 | 1.95 ± 0.40 | 1.66 ± 0.27 | 1.62 ± 0.33 | 1.62 ± 0.48 | 1.56 ± 0.64 | 1.9 ± 0.69 | 1.79 ± 0.84 | 1.54 ± 0.41 | 1.62 ± 0.51

    PMID 32791973 · one of two readings recorded this

  • serum potassium 0 h and 48 h by Step

    K (mEq/l) | 4.1 ± 0.4 | 4.0 ± 0.1 | 4.2 ± 0.5 | 4.6 ± 0.9 | 4.3 ± 0.4 | 4.1 ± 0.2 | 4.2 ± 0.5 | 4.5 ± 0.5 | 4.3 ± 0.5 | 4.3 ± 0.5

    PMID 32791973 · one of two readings recorded this

  • serum sodium 0 h and 48 h by Step

    Na (mEq/l) | 140.0 ± 2.2 | 138.5 ± 0.7 | 140.6 ± 3.5 | 138.8 ± 5.1 | 140.0 ± 2.9 | 138.3 ± 2.5 | 140.6 ± 3.6 | 140.0 ± 2.9 | 137.2 ± 3.3 | 136.2 ± 2.6

    PMID 32791973 · one of two readings recorded this

  • WBC 0 h and 48 h by Step

    WBC (K/μl) | 6.9 ± 3.4 | 8.5 ± 1.4 | 8.9 ± 2.1 | 9.0 ± 1.8 | 10.1 ± 2.9 | 9.2 ± 2.0 | 9.3 ± 2.8 | 8.2 ± 2.3 | 10.2 ± 5.7 | 8.8 ± 2.5

    PMID 32791973 · one of two readings recorded this

  • whole blood NAD+

    unclear, p = 0.19

    NPRT treatment (all Steps combined) demonstrated an 80% increase in NAD+ levels compared to placebo at 48 h, although this difference was not statistically significant (p = 0.19)

    PMID 32791973 · one of two readings recorded this

  • whole blood NAD+

    increases, p = 0.04

    only the increase with NRPT Step 2 (dose 500 mg/100 mg) reached statistical significance (47%, p = 0.04)

    PMID 32791973 · one of two readings recorded this

  • whole blood NAD+

    unclear

    The highest mean increase in NAD+ was achieved in Step 3 (67%, dose 750 mg/150 mg), but this increase was not statistically significant

    PMID 32791973 · one of two readings recorded this

  • whole blood NAD+

    increases, p = 0.002

    NRPT treatment demonstrated a significant increase in whole blood NAD+ levels at 48 h compared to baseline (37%, p = 0.002)

    PMID 32791973 · one of two readings recorded this

  • whole blood NAD+

    decreases, p = 0.05

    whole blood NAD+ levels in patients with AKI receiving placebo decreased by 50% at 48 h (p = 0.05, Fig. 3a)

    PMID 32791973 · one of two readings recorded this

  • mean arterial pressure

    no effect, p = 0.653

    Day 1 | 102 (97–107) | 103 (97–109) | 0.653

    PMID 34191033 · one of two readings recorded this

  • mean arterial pressure

    no effect, p = 0.976

    Day 15 | 102 (97–107) | 102 (96–108) | 0.976

    PMID 34191033 · one of two readings recorded this

  • mean arterial pressure

    no effect, p = 0.738

    Day 29 | 99.4 (93.5–105) | 98.5 (94.0–103) | 0.738

    PMID 34191033 · one of two readings recorded this

  • basal metabolic rate

    no effect, p = 0.824

    Basal metabolic rates and fasting RERs were similar between INT and CON (P = 0.824 and P = 0.297, respectively

    PMID 34191033 · one of two readings recorded this

  • body fat percentage

    no effect, p = 0.121

    34.2% (95% CI: 29.3%, 39.2%) and 33.3% (95% CI: 27.6%, 38.9%), respectively; P = 0.121

    PMID 34191033 · one of two readings recorded this

  • body weight

    no effect, p = 0.812

    Body weight did not differ between INT (73.0 kg; 95% CI: 68.6 kg, 77.5 kg) and CON (72.9 kg; 95% CI: 68.6 kg,77.2 kg; P = 0.812)

    PMID 34191033 · one of two readings recorded this

  • cycling carbohydrate oxidation rate

    no effect, p = 0.186

    nor did cycling RER, carbohydrate oxidation, or lipid oxidation rates (P = 0.366, 0.186, and 0.466, respectively; Figure 5F–H)

    PMID 34191033 · one of two readings recorded this

  • cycling lipid oxidation rate

    no effect, p = 0.466

    nor did cycling RER, carbohydrate oxidation, or lipid oxidation rates (P = 0.366, 0.186, and 0.466, respectively; Figure 5F–H)

    PMID 34191033 · one of two readings recorded this

  • cycling respiratory exchange ratio

    no effect, p = 0.366

    nor did cycling RER, carbohydrate oxidation, or lipid oxidation rates (P = 0.366, 0.186, and 0.466, respectively; Figure 5F–H)

    PMID 34191033 · one of two readings recorded this

  • cytochrome C response

    no effect, p = 0.368

    CytC responses were, on average, 1.32% for INT and 0.73% for CON, and did not differ between conditions (P = 0.368)

    PMID 34191033 · one of two readings recorded this

  • diastolic blood pressure

    no effect, p = 0.551

    Day 1 | 82.9 (77.6–88.2) | 84.3 (80.0–88.6) | 0.551

    PMID 34191033 · one of two readings recorded this

  • diastolic blood pressure

    no effect, p = 0.733

    Day 15 | 82.9 (78.1–87.8) | 83.8 (78.5–89.0) | 0.733

    PMID 34191033 · one of two readings recorded this

  • diastolic blood pressure

    no effect, p = 0.433

    Day 29 | 81.1 (75.1–87.0) | 79.4 (74.8–84.1) | 0.433

    PMID 34191033 · one of two readings recorded this

  • ex vivo State 2 respiration (malate + glutamate)

    unclear, p = 0.01

    although a slight but significant difference of malate + glutamate (MG; P = 0.010) was observed between INT and CON

    PMID 34191033 · one of two readings recorded this

  • fasted carbohydrate oxidation

    no effect, p = 0.588

    neither carbohydrate nor lipid oxidation in the fasted state was different between INT and CON [P = 0.588 and P = 0.787, respectively]

    PMID 34191033 · one of two readings recorded this

  • fasted lipid oxidation

    no effect, p = 0.787

    neither carbohydrate nor lipid oxidation in the fasted state was different between INT and CON [P = 0.588 and P = 0.787, respectively]

    PMID 34191033 · one of two readings recorded this

  • fasting respiratory exchange ratio

    no effect, p = 0.297

    Basal metabolic rates and fasting RERs were similar between INT and CON (P = 0.824 and P = 0.297, respectively

    PMID 34191033 · one of two readings recorded this

  • gross exercise efficiency (GEE)

    no effect, p = 0.419

    GEE did not differ between conditions (P = 0.419; Figure 5I)

    PMID 34191033 · one of two readings recorded this

  • intrahepatic lipid content

    no effect, p = 0.624

    Intrahepatic lipid content was measured noninvasively by 1H-MRS and did not differ between INT (2.8%; 0.8%–4.8%) and CON (2.7%; 1.1%–4.3%; P = 0.624)

    PMID 34191033 · one of two readings recorded this

  • maximal uncoupled respiration (State 3U)

    no effect, p = 0.495

    Maximal uncoupled respiration (State 3U), a reflection of the maximal capacity of the electron transport chain, did not differ between INT and CON (P = 0.495; Figure 4E)

    PMID 34191033 · one of two readings recorded this

  • mitochondrial proton leak (State 4o)

    no effect, p = 0.888

    mitochondrial proton leak (State 4o) was assessed through the addition of oligomycin and did not differ between INT and CON (P = 0.888; Figure 4F)

    PMID 34191033 · one of two readings recorded this

  • net exercise efficiency (NEE)

    no effect, p = 0.636

    NEE (i.e., GEE corrected for the BMR) was also not different between conditions (P = 0.636; Figure 5J)

    PMID 34191033 · one of two readings recorded this

  • plasma free fatty acids

    no effect, p = 0.812

    Concentrations of FFA showed no differences between INT (496 μmol/L; 95% CI: 397, 595 μmol/L) and CON (512 μmol/L; 95% CI: 416, 609 μmol/L; P = 0.812]

    PMID 34191033 · one of two readings recorded this

  • plasma glucose

    no effect, p = 0.223

    Glucose concentrations did not differ for INT (5.87 mmol/L; 95% CI: 5.57, 6.16 mmol/L) and CON (5.76 mmol/L; 95% CI: 5.52, 6.01 mmol/L; P = 0.223)

    PMID 34191033 · one of two readings recorded this

  • plasma insulin

    no effect, p = 0.807

    insulin levels were not different between INT (9.41 mU/L; 95% CI: 4.18, 14.7 mU/L) and CON (9.12 mU/L; 95% CI: 5.40, 12.8 mU/L; P = 0.807)

    PMID 34191033 · one of two readings recorded this

  • plasma triglycerides

    no effect, p = 0.266

    plasma TG levels were not different between INT (0.830 mmol/L; IQR, 0.675–1.03 mmol/L) and CON (0.990 mmol/L; IQR, 0.610–1.43 mmol/L; P = 0.266)

    PMID 34191033 · one of two readings recorded this

  • RAND-36 other 8 domains

    no effect, p = 0.05

    the other 8 out of 9 domains of the RAND-36 did not show any differences between INT and CON on Day 29 (P ≥ 0.05; Figure 6)

    PMID 34191033 · one of two readings recorded this

  • RAND-36 perceived physical functioning domain

    increases, p = 0.031, n = 12

    significantly higher scores were observed for the perceived physical functioning domain in INT (92.0; IQR, 90.0–100) as compared to CON (90.0; IQR, 86.3–93.8; n = 12; P = 0.031)

    PMID 34191033 · one of two readings recorded this

  • skeletal muscle acylcarnitine subgroups

    no effect, p = 0.05, n = 11

    no differences were observed in the concentrations of acylcarnitine subgroups between INT and CON (P ≥ 0.05;; n = 11)

    PMID 34191033 · one of two readings recorded this

  • skeletal muscle ADP riboside (ADPr)

    no effect, p = 0.413, n = 11

    with no differences observed in ADPr levels between INT and CON (P = 0.413; n = 11; Figure 2)

    PMID 34191033 · one of two readings recorded this

  • skeletal muscle methyl-nicotinamide (MeNAM)

    increases, p = 0.001

    revealed significantly higher MeNAM concentrations in INT compared to CON (P = 0.001; Figure 2)

    PMID 34191033 · one of two readings recorded this

  • skeletal muscle NAAD

    no effect, p = 0.262, n = 11

    which was not different between INT and CON (P = 0.262; n = 11; Figure 2)

    PMID 34191033 · one of two readings recorded this

  • skeletal muscle NAD(H)

    no effect, p = 0.389, n = 11

    The respective reduced forms, NAD(H) and NAD(P)H, also did not differ between conditions (P = 0.389 and P = 0.365 respectively; n = 11; Figure 2)

    PMID 34191033 · one of two readings recorded this

  • skeletal muscle NAD+ level

    no effect, p = 0.123

    These analyses showed that NAD+ levels were similar between INT and CON (P = 0.123)

    PMID 34191033 · one of two readings recorded this

  • skeletal muscle NAD(P)H

    no effect, p = 0.365, n = 11

    The respective reduced forms, NAD(H) and NAD(P)H, also did not differ between conditions (P = 0.389 and P = 0.365 respectively; n = 11; Figure 2)

    PMID 34191033 · one of two readings recorded this

  • skeletal muscle NAD(P)+

    no effect, p = 0.833, n = 11

    which did not differ between conditions (P = 0.833; n = 11; Figure 2)

    PMID 34191033 · one of two readings recorded this

  • SPPB balance test

    no effect, p = 0.999

    Scores for the balance test, the walking speed, and the chair-rise test were similar between INT and CON (P > 0.999, P = 0.500, and P = 0.489, respectively)

    PMID 34191033 · one of two readings recorded this

  • SPPB chair-rise test

    no effect, p = 0.489

    Scores for the balance test, the walking speed, and the chair-rise test were similar between INT and CON (P > 0.999, P = 0.500, and P = 0.489, respectively)

    PMID 34191033 · one of two readings recorded this

  • SPPB overall score

    no effect, p = 0.999

    The overall score on the SPPB was also not different between INT (11.0; IQR, 10.00–11.5) and CON (11.0; IQR, 9.50–12.0; P > 0.999)

    PMID 34191033 · one of two readings recorded this

  • SPPB walking speed

    no effect, p = 0.5

    Scores for the balance test, the walking speed, and the chair-rise test were similar between INT and CON (P > 0.999, P = 0.500, and P = 0.489, respectively)

    PMID 34191033 · one of two readings recorded this

  • State 3 respiration, complex I-linked lipid substrates (malate + octanoyl-carnitine)

    no effect, p = 0.882

    Also, the assessment of ADP-stimulated (State 3) respiration fueled by complex I-linked substrates (malate and octanoyl-carnitine; Figure 4B, P = 0.882) did not reveal any differences between INT and CON

    PMID 34191033 · one of two readings recorded this

  • State 3 respiration, malate + glutamate (MG)

    no effect, p = 0.054

    If anything, state 3 respiration upon MG tended to be lower in INT compared with CON (P = 0.054; Figure 4C)

    PMID 34191033 · one of two readings recorded this

  • State 3 respiration, malate + glutamate + succinate

    no effect, p = 0.388

    or malate + glutamate + succinate (P = 0.388; Figure 4D)

    PMID 34191033 · one of two readings recorded this

  • State 3 respiration, malate + octanoyl-carnitine + glutamate + succinate

    no effect, p = 0.716

    malate + octanoyl-carnitine + glutamate + succinate (P = 0.716)

    PMID 34191033 · one of two readings recorded this

  • State 3 respiration, malate + octanoyl-carnitine + glutamate

    no effect, p = 0.753

    State 3 respiration upon parallel electron input into complexes I and II showed no differences between INT and CON with the substrate combinations malate + octanoyl-carnitine + glutamate (P = 0.753)

    PMID 34191033 · one of two readings recorded this

  • supplement compliance (sachets consumed)

    For the supplementation with precursors (INT), 100% of all sachets were consumed, compared to 99% (range, 97%–100%) in the control condition (CON)

    PMID 34191033 · one of two readings recorded this

  • systolic blood pressure

    no effect, p = 0.821

    Day 1 | 140 (131–148) | 141 (131–151) | 0.821

    PMID 34191033 · one of two readings recorded this

  • systolic blood pressure

    no effect, p = 0.741

    Day 15 | 140 (131–149) | 139 (129–148) | 0.741

    PMID 34191033 · one of two readings recorded this

  • systolic blood pressure

    no effect, p = 0.877

    Day 29 | 136 (128–145) | 137 (130–143) | 0.877

    PMID 34191033 · one of two readings recorded this

  • total energy expenditure during submaximal cycling

    no effect, p = 0.103

    The total energy expenditure during cycling did not differ between INT and CON (P = 0.103; Figure 5E)

    PMID 34191033 · one of two readings recorded this

  • vastus lateralis muscle volume

    no effect, p = 0.45, n = 11

    Muscle volume of the m. vastus lateralis, assessed by MRI, was not different for INT (1700 cm3; 1440–1960 cm3) compared to CON (1710 cm3; 1450–1980 cm3; n = 11; P = 0.450)

    PMID 34191033 · one of two readings recorded this

  • ATP + ADP

    increases, p = 0.029

    This difference is significant on Day 5, when the RiaGev group was 7.3% higher than the Placebo group (p = 0.029)

    PMID 35684021 · one of two readings recorded this

  • blood NAD+ concentration

    increases, p = 0.044

    At day 5, the NAD+ concentration in RiaGev group was significantly higher than that at Day 1, a 10.4% increase (p = 0.034), which is also significantly higher than that in the placebo group (p = 0.044)

    PMID 35684021 · one of two readings recorded this

  • blood NAD+ concentration

    increases, p = 0.034

    At day 5, the NAD+ concentration in RiaGev group was significantly higher than that at Day 1, a 10.4% increase (p = 0.034), which is also significantly higher than that in the placebo group (p = 0.044)

    PMID 35684021 · one of two readings recorded this

  • blood NAD+ concentration

    unclear, p = 0.07

    At Day 8, there is also a trending significant increase of 6.4% in NAD+ concentration over baseline (p = 0.07)

    PMID 35684021 · one of two readings recorded this

  • blood NAD+ + NADP+ concentration

    increases, p = 0.029

    When combined, NAD+ + NADP+ concentrations observed at Days 5 and 8 were significantly higher than that in Placebo (p ≤ 0.029, Figure 2c)

    PMID 35684021 · one of two readings recorded this

  • blood NAD+ + NADP+ concentration

    increases, p = 0.032

    significant within-group concentration increases of 9.4%, 14.8% and 9.7% reported within RiaGev group at Days 3, 5, and 8 respectively (p ≤ 0.032)

    PMID 35684021 · one of two readings recorded this

  • blood NAD+ + NADP+ concentration

    increases, p = 0.032

    significant within-group concentration increases of 9.4%, 14.8% and 9.7% reported within RiaGev group at Days 3, 5, and 8 respectively (p ≤ 0.032)

    PMID 35684021 · one of two readings recorded this

  • blood NAD+ + NADP+ concentration

    increases, p = 0.032

    significant within-group concentration increases of 9.4%, 14.8% and 9.7% reported within RiaGev group at Days 3, 5, and 8 respectively (p ≤ 0.032)

    PMID 35684021 · one of two readings recorded this

  • blood NADP+ concentration

    increases, p = 0.04

    The NADP+ concentrations for the RiaGev group are also significantly greater than that of Placebo group at Day 5 and 8 (p ≤ 0.04)

    PMID 35684021 · one of two readings recorded this

  • blood NADP+ concentration

    increases, p = 0.008

    Significant within-group increases of 19.1%, 27.6%, and 19.6% were recorded with RiaGev group at Days 3, 5, and 8 over baseline, respectively (p ≤ 0.008)

    PMID 35684021 · one of two readings recorded this

  • blood NADP+ concentration

    increases, p = 0.008

    Significant within-group increases of 19.1%, 27.6%, and 19.6% were recorded with RiaGev group at Days 3, 5, and 8 over baseline, respectively (p ≤ 0.008)

    PMID 35684021 · one of two readings recorded this

  • blood NADP+ concentration

    increases, p = 0.008

    Significant within-group increases of 19.1%, 27.6%, and 19.6% were recorded with RiaGev group at Days 3, 5, and 8 over baseline, respectively (p ≤ 0.008)

    PMID 35684021 · one of two readings recorded this

  • blood NADP+ + NADPH concentration

    increases, p = 0.05

    the nicotinamide adenine dinucleotide phosphates in the RiaGev group increased significantly at 8.3%, 22.5%, and 12.9% at Days 3, 5, and 8, respectively, compared to the Placebo group and over the baseline (p < 0.05)

    PMID 35684021 · one of two readings recorded this

  • blood NADP+ + NADPH concentration

    increases, p = 0.05

    the nicotinamide adenine dinucleotide phosphates in the RiaGev group increased significantly at 8.3%, 22.5%, and 12.9% at Days 3, 5, and 8, respectively, compared to the Placebo group and over the baseline (p < 0.05)

    PMID 35684021 · one of two readings recorded this

  • blood NADP+ + NADPH concentration

    increases, p = 0.05

    the nicotinamide adenine dinucleotide phosphates in the RiaGev group increased significantly at 8.3%, 22.5%, and 12.9% at Days 3, 5, and 8, respectively, compared to the Placebo group and over the baseline (p < 0.05)

    PMID 35684021 · one of two readings recorded this

  • blood NADPH concentration

    no effect, p = 0.08

    There was only a trending increase in NADPH in the RiaGev group compared to the Placebo group (p >0.08)

    PMID 35684021 · one of two readings recorded this

  • CIS concentration improvement

    increases, p = 0.014

    Concentration in the RiaGev group also improved significantly by 22.9% (p = 0.014), 19.8% (p = 0.012) and 14.3% (p = 0.118) at Days 3, 5, and 8, respectively

    PMID 35684021 · one of two readings recorded this

  • CIS concentration improvement

    increases, p = 0.012

    Concentration in the RiaGev group also improved significantly by 22.9% (p = 0.014), 19.8% (p = 0.012) and 14.3% (p = 0.118) at Days 3, 5, and 8, respectively

    PMID 35684021 · one of two readings recorded this

  • CIS concentration improvement

    unclear, p = 0.118

    Concentration in the RiaGev group also improved significantly by 22.9% (p = 0.014), 19.8% (p = 0.012) and 14.3% (p = 0.118) at Days 3, 5, and 8, respectively

    PMID 35684021 · one of two readings recorded this

  • CIS motivation improvement

    unclear, p = 0.13

    the RiaGev group improved by 20.4% (p = 0.13), 22.2% (p = 0.015), and 14% (p = 0.163) at Days 3, 5, and 8, respectively

    PMID 35684021 · one of two readings recorded this

  • CIS motivation improvement

    increases, p = 0.015

    the RiaGev group improved by 20.4% (p = 0.13), 22.2% (p = 0.015), and 14% (p = 0.163) at Days 3, 5, and 8, respectively

    PMID 35684021 · one of two readings recorded this

  • CIS motivation improvement

    unclear, p = 0.163

    the RiaGev group improved by 20.4% (p = 0.13), 22.2% (p = 0.015), and 14% (p = 0.163) at Days 3, 5, and 8, respectively

    PMID 35684021 · one of two readings recorded this

  • CIS physical fatigue improvement

    increases

    At Days 3, 5, and 8, the physical fatigue improved by 24.3% (p = 0.003) vs. 13.6% (p = 0.041), 21.2% (p = 0.009) vs. 11.6% (p = 0.08), 15.1% (p = 0.132) vs. 7.4% (p = 0.17) in the RiaGev vs. Placebo groups, respectively

    PMID 35684021 · one of two readings recorded this

  • CIS physical fatigue improvement

    increases

    At Days 3, 5, and 8, the physical fatigue improved by 24.3% (p = 0.003) vs. 13.6% (p = 0.041), 21.2% (p = 0.009) vs. 11.6% (p = 0.08), 15.1% (p = 0.132) vs. 7.4% (p = 0.17) in the RiaGev vs. Placebo groups, respectively

    PMID 35684021 · one of two readings recorded this

  • CIS physical fatigue improvement

    increases

    At Days 3, 5, and 8, the physical fatigue improved by 24.3% (p = 0.003) vs. 13.6% (p = 0.041), 21.2% (p = 0.009) vs. 11.6% (p = 0.08), 15.1% (p = 0.132) vs. 7.4% (p = 0.17) in the RiaGev vs. Placebo groups, respectively

    PMID 35684021 · one of two readings recorded this

  • CIS total score improvement

    increases

    At Days 3, 5, and 8, the total CIS scores were improved by 21.5% (p = 0.04) vs. 10.4% (p = 0.07), 18.3% (p = 0.014) vs. 6.2% (p = 0.049), and 12.7% (p = 0.15) vs. 4.1% (p = 0.361) in the RiaGev vs. the Placebo group, respectively

    PMID 35684021 · one of two readings recorded this

  • CIS total score improvement

    increases

    At Days 3, 5, and 8, the total CIS scores were improved by 21.5% (p = 0.04) vs. 10.4% (p = 0.07), 18.3% (p = 0.014) vs. 6.2% (p = 0.049), and 12.7% (p = 0.15) vs. 4.1% (p = 0.361) in the RiaGev vs. the Placebo group, respectively

    PMID 35684021 · one of two readings recorded this

  • CIS total score improvement

    increases

    At Days 3, 5, and 8, the total CIS scores were improved by 21.5% (p = 0.04) vs. 10.4% (p = 0.07), 18.3% (p = 0.014) vs. 6.2% (p = 0.049), and 12.7% (p = 0.15) vs. 4.1% (p = 0.361) in the RiaGev vs. the Placebo group, respectively

    PMID 35684021 · one of two readings recorded this

  • OGTT blood glucose iAUC

    decreases, p = 0.013

    the blood glucose iAUC level of RiaGev group at Day 8 was significantly lower compared to Day 1 (1700.42 vs. 662.50, respectively, p = 0.013)

    PMID 35684021 · one of two readings recorded this

  • OGTT glucose peak at 15 min

    no effect

    despite the glucose peak remaining the same (116 vs. 114 mg/dL at 15 min post-prandial at Day 8 vs. Day 1, respectively, Figure 3a)

    PMID 35684021 · one of two readings recorded this

  • OGTT insulin peak

    increases

    the insulin peak on Day 8 was higher than on Day 1 (74 vs. 67 μU/mL, respectively, Figure 3c)

    PMID 35684021 · one of two readings recorded this

  • OGTT overall insulin level

    no effect, p = 0.793

    the overall insulin level of RiaGev group at Day 8 was not significantly different from Day 1 (p = 0.793)

    PMID 35684021 · one of two readings recorded this

  • OGTT total blood glucose AUC (0-120 min)

    no effect

    the Placebo group did not change significantly (12,041.55 on Day 1 vs. 11,914.8 on Day 8)

    PMID 35684021 · one of two readings recorded this

  • OGTT total blood glucose AUC (0-120 min)

    decreases

    RiaGev reduced blood glucose AUC 4.92% (from 12,771.15 on Day 1 to 12,143.17 on Day 8) after 7-day supplementation

    PMID 35684021 · one of two readings recorded this

  • supplement compliance

    The compliance for taking RiaGev and Placebo supplementations is 100%

    PMID 35684021 · one of two readings recorded this

  • total glutathione (GSH + GSSG)

    increases, p = 0.016

    There was a significant increase of total glutathione (GSH + GSSG) at Day 3 and 5 (10.2% and 11.6%, respectively) in the RiaGev group over baseline (p ≤ 0.016)

    PMID 35684021 · one of two readings recorded this

  • total glutathione (GSH + GSSG)

    increases, p = 0.016

    There was a significant increase of total glutathione (GSH + GSSG) at Day 3 and 5 (10.2% and 11.6%, respectively) in the RiaGev group over baseline (p ≤ 0.016)

    PMID 35684021 · one of two readings recorded this

  • waking salivary cortisol

    decreases, p = 0.044

    There was a significant between-group difference in waking salivary cortisol at Day 5 and Day 8, where the RiaGev group displayed lower levels of cortisol than the placebo group (p = 0.044)

    PMID 35684021 · one of two readings recorded this

The whole record — 382 rows